Health Boards
TNF (Tumor necrosis factor) inhibitors are a modern popular choice for the treatment of PsA (psoriatic arthritis), and a report by Frost & Sullivan a growth partnership company, suggests there is a need for drug manufacturers to work harder on low cost alternatives. The research finds that psoriatic arthritis pharmacotherapeutics prescribed as add-on therapies to standard background therapy earned revenues of approximately $751.5 million in 2011, and is estimated to reach $1.3 billion in 2017.
"While TNF inhibitors have laid the groundwork for the next generation of effective, disease-modifying biologics, the need of the hour is patient-friendly options with improved profiles, such as oral administration or enhanced tolerability," said Frost & Sullivan Senior Industry Analyst Deborah Toscano. "These novel drugs could offer better long-term clinical outcomes."
"With the impending launch of three new therapies for the treatment of PsA in 2014, the awareness of PsA is expected to increase substantially," noted Toscano. "This will renew interest in PsA, as patients and physicians will finally be presented with alternative treatments."
"However, slow uptake of these new drugs by a conservative regulatory and medical community is likely until they are proven in the market. To gain end-user confidence, companies must make products with a high degree of safety, with significant clinical or economic benefits over TNF inhibitors."
"While TNF inhibitors have laid the groundwork for the next generation of effective, disease-modifying biologics, the need of the hour is patient-friendly options with improved profiles, such as oral administration or enhanced tolerability," said Frost & Sullivan Senior Industry Analyst Deborah Toscano. "These novel drugs could offer better long-term clinical outcomes."
"With the impending launch of three new therapies for the treatment of PsA in 2014, the awareness of PsA is expected to increase substantially," noted Toscano. "This will renew interest in PsA, as patients and physicians will finally be presented with alternative treatments."
"However, slow uptake of these new drugs by a conservative regulatory and medical community is likely until they are proven in the market. To gain end-user confidence, companies must make products with a high degree of safety, with significant clinical or economic benefits over TNF inhibitors."